Does Medicare Cover Kidney Cancer Treatment — Complete Guide 2026
Does Medicare cover kidney cancer treatment in 2026? Kidney cancer — primarily renal cell carcinoma (RCC) — is the seventh most common cancer in men and the ninth most common cancer in women with approximately 80,000 new cases diagnosed annually. The majority of kidney cancer cases occur in people over 60 — making Medicare coverage critically important for this population. The good news is that yes — does Medicare cover kidney cancer treatment in 2026 — comprehensively across all stages including surgery, immunotherapy, targeted therapy, and combination regimens. In this complete guide we explain exactly what Medicare covers for kidney cancer treatment in 2026. All information is sourced from Medicare.gov and CMS.gov.
Also Read —
- Does Medicare Cover Cancer Treatment 2026
- Medicare for People Under 65 with Disability — Complete Guide 2026
- Medicare Part B vs Part D Drug Coverage 2026
What You Will Learn — Does Medicare Cover Kidney Cancer
- Does Medicare cover kidney cancer treatment in 2026
- Does Medicare cover nephrectomy surgery for kidney cancer
- Does Medicare cover immunotherapy for kidney cancer
- Does Medicare cover targeted therapy for kidney cancer
- Does Medicare cover combination therapy for kidney cancer
- Does Medicare cover ablative therapy for kidney cancer
- How much does kidney cancer treatment cost with Medicare
- Does Medicare Advantage cover kidney cancer
- Frequently asked questions about Medicare kidney cancer coverage 2026
Does Medicare Cover Kidney Cancer Treatment in 2026?
Yes — does Medicare cover kidney cancer treatment in 2026 — comprehensively across all stages and treatment modalities. Medicare Part A covers inpatient nephrectomy surgery. Medicare Part B covers IV immunotherapy infusions, IV targeted therapy, ablative procedures, and physician visits. Medicare Part D covers oral targeted therapy agents including tyrosine kinase inhibitors and other oral medications. The combination of Medicare Part B immunotherapy coverage and Part D targeted therapy coverage — both with strong financial protections — makes Medicare coverage particularly valuable for kidney cancer patients.
Kidney cancer treatment has been transformed over the past decade by the development of checkpoint inhibitor immunotherapy and targeted therapies — with combination regimens now achieving remarkable outcomes for metastatic renal cell carcinoma. Medicare covers all FDA-approved treatment combinations for kidney cancer — making does Medicare cover kidney cancer one of the most important coverage questions for older adults diagnosed with this condition.
Does Medicare Cover Kidney Cancer Diagnosis?
Does Medicare cover diagnostic workup for kidney cancer in 2026? Yes — Medicare Part B covers all major diagnostic procedures for kidney cancer.
CT Scan — Covered
CT scan of abdomen and pelvis with contrast — the primary imaging study for kidney cancer diagnosis and staging — covered at 80% after the $257 annual Part B deductible.
MRI — Covered
MRI of abdomen for detailed kidney tumor characterization — covered at 80% after deductible.
PET Scan — Covered
PET scan for evaluating metastatic disease — covered at 80% after deductible.
Biopsy — Covered
CT-guided kidney biopsy for tissue diagnosis — covered at 80% after deductible when tissue confirmation is needed before treatment.
Bone Scan — Covered
Bone scan for evaluating bone metastases — covered at 80%.
Laboratory Tests — Covered at $0
Complete blood count — covered at $0 Comprehensive metabolic panel — covered at $0 LDH (lactate dehydrogenase) — covered at $0 — prognostic marker for kidney cancer Calcium level — covered at $0 Urinalysis — covered at $0
Molecular Testing — Covered
VHL mutation analysis and comprehensive genomic profiling — covered for guiding treatment decisions.
Does Medicare Cover Nephrectomy Surgery for Kidney Cancer?
Does Medicare cover nephrectomy surgery for kidney cancer in 2026? Yes — Medicare covers all major kidney cancer surgical procedures.
Radical Nephrectomy — Covered
Radical nephrectomy — complete removal of the kidney — the standard surgical treatment for localized kidney cancer — covered under Medicare Part A for inpatient procedures.
Partial Nephrectomy — Covered
Partial nephrectomy — nephron-sparing surgery removing only the tumor while preserving the remaining kidney — covered. Preferred approach for tumors 4 cm or smaller and in patients with reduced kidney function.
Laparoscopic Nephrectomy — Covered
Minimally invasive laparoscopic radical or partial nephrectomy — covered at standard surgical rates.
Robotic-Assisted Nephrectomy — Covered
Robot-assisted nephrectomy using da Vinci system — covered. Medicare pays standard surgical rate — robotic cost included in facility charge.
Cytoreductive Nephrectomy — Covered
Nephrectomy for metastatic kidney cancer to reduce tumor burden before systemic therapy — covered for appropriate patients.
Lymph Node Dissection — Covered
Regional lymph node dissection when indicated — covered as part of the surgical procedure.
Nephrectomy Costs with Medicare
Inpatient radical nephrectomy:
- Part A deductible — $1,676 per benefit period
- Days 1 to 60 — $0 after deductible
- Surgeon fee — 20% Part B coinsurance
With Medigap Plan G — nephrectomy surgery costs $0 after the $257 annual Part B deductible — covering both the $1,676 Part A deductible and all surgeon coinsurance.
Does Medicare Cover Immunotherapy for Kidney Cancer?
Does Medicare cover immunotherapy for kidney cancer in 2026? Yes — and this is one of the most important Medicare kidney cancer coverage questions given that immunotherapy has transformed RCC treatment.
PD-1/PD-L1 Checkpoint Inhibitors — Part B
All major checkpoint inhibitors for kidney cancer covered under Medicare Part B at 80% after the deductible:
Pembrolizumab (Keytruda) — covered Part B:
- Keytruda plus lenvatinib (Lenvima) — first-line combination for advanced RCC
- Keytruda plus axitinib — first-line combination
- Keytruda adjuvant — for high-risk localized RCC after nephrectomy
- Medicare-approved per infusion — approximately $20,000 to $25,000
- Your 20% coinsurance — approximately $4,000 to $5,000 per infusion
- Annual coinsurance without supplement — approximately $35,000 to $87,000
With Medigap Plan G — Keytruda costs $0 after the $257 annual deductible — saving $35,000 to $87,000 per year.
Nivolumab (Opdivo) — covered Part B:
- Opdivo plus Yervoy (ipilimumab) — first-line combination for intermediate and poor-risk RCC — covered Part B
- Opdivo adjuvant — for high-risk localized RCC — covered Part B
- Opdivo monotherapy — second-line — covered Part B
Avelumab (Bavencio) — covered Part B for first-line maintenance in RCC.
Does Medicare Cover Targeted Therapy for Kidney Cancer?
Does Medicare cover targeted therapy for kidney cancer in 2026? Yes — Medicare covers all major targeted therapies for RCC through Part B and Part D depending on administration route.
VEGF-Targeted TKIs — Part D
Oral tyrosine kinase inhibitors targeting VEGF — covered under Medicare Part D:
Sunitinib (Sutent) — covered Part D:
- First-generation TKI for RCC — oral once daily 4 weeks on 2 weeks off
- Retail cost approximately $9,000 to $12,000 per month
- $2,000 annual Part D maximum — critical protection
Pazopanib (Votrient) — covered Part D:
- Oral daily TKI for advanced RCC
- $2,000 annual Part D maximum
Sorafenib (Nexavar) — covered Part D — $2,000 cap
Axitinib (Inlyta) — covered Part D:
- Used in combination with pembrolizumab or avelumab
- Retail approximately $10,000 to $13,000 per month
- $2,000 annual Part D maximum
Cabozantinib (Cabometyx) — covered Part D:
- Second-line and combination regimens
- Retail approximately $12,000 to $15,000 per month
- $2,000 annual Part D maximum
Lenvatinib (Lenvima) — covered Part D:
- Used in combination with pembrolizumab
- Retail approximately $16,000 to $19,000 per month
- $2,000 annual Part D maximum — saves $190,000 to $226,000 per year
Tivozanib (Fotivda) — covered Part D — $2,000 cap
mTOR Inhibitors — Part D
Everolimus (Afinitor) — covered Part D — $2,000 annual cap Temsirolimus (Torisel) — IV — covered Part B at 80% after deductible
HIF-2α Inhibitor — Part D
Belzutifan (Welireg) — covered Part D for VHL-related RCC and advanced clear cell RCC:
- Oral daily — retail approximately $17,000 to $20,000 per month
- $2,000 annual Part D maximum — saves $202,000 to $238,000 per year
- Most recently approved targeted therapy for RCC
Does Medicare Cover Combination Regimens for Kidney Cancer?
Does Medicare cover combination immunotherapy and targeted therapy for kidney cancer in 2026? Yes — all FDA-approved combination regimens are covered through appropriate Medicare pathways.
Opdivo Plus Yervoy — Both Part B
Nivolumab plus ipilimumab combination — both drugs covered Part B at 80% after deductible. First-line for intermediate and poor-risk advanced RCC. Combined coinsurance significant without supplement — $0 with Medigap Plan G.
Keytruda Plus Axitinib — Split Coverage
Pembrolizumab (Part B) plus axitinib (Part D):
- Keytruda infusions covered Part B at 80% — Plan G $0
- Axitinib oral covered Part D — $2,000 annual cap
- Dual pathway protection for both components
Keytruda Plus Lenvima — Split Coverage
Pembrolizumab (Part B) plus lenvatinib (Part D):
- Keytruda covered Part B — Plan G $0
- Lenvima covered Part D — $2,000 cap saves $190,000 to $226,000
- Both components comprehensively protected
Opdivo Plus Cabometyx — Split Coverage
Nivolumab (Part B) plus cabozantinib (Part D):
- Opdivo covered Part B at 80% — Plan G $0
- Cabometyx covered Part D — $2,000 annual cap
- FDA-approved first-line combination
Does Medicare Cover Ablative Therapy for Kidney Cancer?
Does Medicare cover ablative treatments for kidney cancer in 2026? Yes — Medicare Part B covers ablative therapies for small kidney tumors as alternatives to surgery.
Cryoablation — Covered
Cryoablation — using extreme cold to destroy kidney tumors — covered at 80% after deductible for appropriate small tumors particularly in patients with comorbidities limiting surgical risk.
Radiofrequency Ablation — Covered
RFA — using heat to destroy kidney tumors — covered at 80% after deductible.
Microwave Ablation — Covered
Microwave ablation for small renal masses — covered at 80% after deductible.
Stereotactic Body Radiation Therapy (SBRT) — Covered
SBRT for primary kidney tumors and kidney cancer metastases — covered at 80% after deductible.
With Medigap Plan G — all ablative procedures cost $0 after the annual deductible.
Does Medicare Cover Active Surveillance for Kidney Cancer?
Does Medicare cover active surveillance for small kidney tumors in 2026? Yes — active surveillance with regular imaging is covered for small kidney masses being monitored without immediate treatment.
Surveillance Imaging — Covered
Regular CT or MRI imaging for active surveillance of small renal masses — covered at 80% after the deductible. Most surveillance protocols involve imaging every 6 to 12 months.
With Medigap Plan G — all surveillance imaging costs $0 after the annual deductible.
How Much Does Kidney Cancer Treatment Cost with Medicare in 2026?
Diagnosis and Staging
CT PET MRI — approximately $100 to $300 your 20% With Medigap Plan G — $0 after annual deductible
Nephrectomy Surgery
Part A deductible $1,676 plus surgeon 20% Total without supplement approximately $2,500 to $4,000 With Medigap Plan G — $0 after annual deductible
Keytruda Immunotherapy
Without supplement — $35,000 to $87,000 annually your 20% With Medigap Plan G — $0 after annual deductible
Opdivo Plus Yervoy Combination
Both Part B — significant combined coinsurance without supplement With Medigap Plan G — $0 all infusions after annual deductible
Oral Targeted Therapy Part D
Lenvima — $2,000 annual maximum — saves $190,000 to $226,000 Cabometyx — $2,000 annual maximum — saves $142,000 to $178,000 Belzutifan Welireg — $2,000 annual maximum — saves $202,000 to $238,000
Combination Split Coverage
Keytruda (Plan G $0) plus Lenvima ($2,000 Part D cap) — maximum exposure $2,257 first year $2,000 per year in subsequent years for both drugs combined
Does Medicare Advantage Cover Kidney Cancer?
Does Medicare Advantage cover kidney cancer treatment in 2026? Yes — all Medicare Advantage plans must cover kidney cancer treatment.
Prior authorization — required for immunotherapy combinations and oral targeted therapy. In-network surgical oncologist and cancer center — verify before treatment. Annual maximum $9,350 — kidney cancer patients on active treatment reach this quickly. Part D $2,000 maximum — same critical protection for all oral TKIs.
Frequently Asked Questions — Does Medicare Cover Kidney Cancer
Does Medicare cover kidney cancer treatment in 2026?
Yes — does Medicare cover kidney cancer comprehensively in 2026 including nephrectomy surgery, Keytruda and Opdivo immunotherapy at 80% under Part B, oral targeted therapies including Lenvima Cabometyx and Belzutifan under Part D with $2,000 annual cap, combination regimens, and ablative therapy. With Medigap Plan G most kidney cancer treatment costs $0 after the annual deductible.
Does Medicare cover Keytruda for kidney cancer?
Yes — Medicare Part B covers pembrolizumab (Keytruda) for kidney cancer — adjuvant after nephrectomy and first-line for metastatic RCC in combination with lenvatinib or axitinib. Without a supplement annual Keytruda coinsurance can reach $35,000 to $87,000. With Medigap Plan G Keytruda costs $0 after the annual deductible.
Does Medicare cover nephrectomy for kidney cancer?
Yes — Medicare covers radical nephrectomy, partial nephrectomy, laparoscopic, and robotic nephrectomy for kidney cancer. The $1,676 Part A deductible applies for inpatient surgery. With Medigap Plan G nephrectomy costs $0 after the annual deductible.
Does Medicare cover oral targeted therapy for kidney cancer?
Yes — Medicare Part D covers all major oral targeted therapies for kidney cancer including sunitinib, pazopanib, axitinib, cabozantinib, lenvatinib, belzutifan, and everolimus. The $2,000 annual Part D maximum saves patients $142,000 to $238,000 annually depending on the specific drug.
Does Medicare cover Opdivo plus Yervoy for kidney cancer?
Yes — Medicare Part B covers nivolumab plus ipilimumab combination for intermediate and poor-risk advanced RCC at 80% after the $257 annual deductible. With Medigap Plan G the entire combination costs $0 after the annual deductible.
Summary — Does Medicare Cover Kidney Cancer 2026
Does Medicare cover kidney cancer treatment in 2026? Yes — Medicare provides extraordinary comprehensive kidney cancer coverage from nephrectomy surgery through immunotherapy, targeted therapy, combination regimens, and ablative treatment. The financial protections are among the most significant in all of Medicare — Keytruda immunotherapy saves $35,000 to $87,000 annually with Plan G and the $2,000 Part D cap saves $142,000 to $238,000 on oral targeted therapies.
For kidney cancer patients the combination of Medigap Plan G eliminating Part B immunotherapy coinsurance and the $2,000 Part D cap protecting against unlimited oral targeted therapy costs creates extraordinary comprehensive financial protection. Kidney cancer patients receiving combination immunotherapy plus targeted therapy benefit from both protections simultaneously — with maximum annual exposure of approximately $2,257 in the first year and $2,000 in subsequent years.
For free help understanding your Medicare kidney cancer coverage contact your State Health Insurance Assistance Program (SHIP) at shiphelp.org or call Medicare free at 1-800-633-4227.
This guide is for informational purposes only. Always consult your oncologist and verify current Medicare coverage at Medicare.gov.
Sources: Medicare.gov | CMS.gov | SSA.gov | AARP.org
Last updated: April 2026 | Author: James Carter, Independent Medicare Research Analyst
